Dilraj Lama

Dilraj Lama

Auto-generated profile, based on publicly available information

Dilraj Lama

Department of Microbiology, Tumor and Cell Biology, Biomedicum B7, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDilraj Lama
Dilraj Lama
TVThibault Vosselman
Thibault Vosselman
CSCagla Sahin
Cagla Sahin
JPJudit Liano Pons
Judit Liano Pons
CCCarmine P. Cerrato
Carmine P. Cerrato
MAMarie Arsenian-Henriksson
Marie Arsenian-Henriksson
The c-MYC oncogene is activated in over 70% of all human cancers. The intrinsic disorder of the c-MYC transcription factor facilitates molecular interactions that regulate numerous biological pathways, but severely limits efforts to target its function for cancer therapy. Here, we use a reductionist strategy to characterize the dynamic and structural heterogeneity of the c-MYC protein. Using probe-based Molecular Dynamics (MD) simulations and machine learning, we identify a conformational switch in the c-MYC amino-terminal transactivation domain (termed coreMYC) that cycles between a closed, inactive, and an open, active conformation. Using the polyphenol epigallocatechin gallate (EGCG) to modulate the conformational landscape of coreMYC, we show through biophysical and cellular assays that the induction of a closed conformation impedes its interactions with the transformation/transcription domain-associated protein (TRRAP) and the TATA-box binding protein (TBP) which are essential for the transcriptional and oncogenic activities of c-MYC. Together, these findings provide insights into structure-activity relationships of c-MYC, which open avenues towards the development of shape-shifting compounds to target c-MYC as well as other disordered transcription factors for cancer treatment.

7 January 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
DLDilraj Lama
Dilraj Lama
ALAnne-Marie Liberatore
Anne-Marie Liberatore
YFYuri Frosi
Yuri Frosi
JNJessica Nakhle
Jessica Nakhle
NTNatia Tsomaia
Natia Tsomaia
SASerge Auvin
Serge Auvin
We have revealed a non-canonical recognition feature that can modulate the binding kinetics of hydrocarbon stapled-peptides interactions with the eIF4E protein.

6 December 2019 in Protein Science
Verified
Journal Article
Closed access
PDF file
DLDilraj Lama
Dilraj Lama
CVChandra S Verma
Chandra S Verma

22 June 2022 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
PIPrasanna Vasudevan Iyengar
Prasanna Vasudevan Iyengar
DMDieuwke Louise Marvin
Dieuwke Louise Marvin
DLDilraj Lama
Dilraj Lama
TTTuan Zea Tan
Tuan Zea Tan
SSSudha Suriyamurthy
Sudha Suriyamurthy
PDPeter Ten Dijke
Peter Ten Dijke
Patients with bladder cancer often have a poor prognosis due to the highly invasive and metastatic characteristics of bladder cancer cells. Epithelial-to-mesenchymal transition (EMT) has been causally linked to bladder cancer invasion. The E3 ubiquitin ligase, tumor necrosis factor receptor–associated factor 4 (TRAF4) has been implicated as a tumor promoter in a wide range of cancers. In contrast, here we show that low TRAF4 expression is associated with poor overall survival in patients with bladder cancer. We show that the TRAF4 gene is epigenetically silenced and that ERK mediates TRAF4 phosphorylation, resulting in lower TRAF4 protein levels in bladder cancer cells. In addition, we demonstrate that TRAF4 is inversely correlated with an EMT gene signature/protein marker expression. Functionally, by manipulating TRAF4 expression, we show that TRAF4 regulates EMT genes and epithelial and invasive properties in bladder cancer cells. Transcriptomic analysis of dysregulated TRAF4 expression in bladder cancer cell lines revealed that high TRAF4 expression enhances the bone morphogenetic protein (BMP)/SMAD and inhibits the NF-κB signaling pathway. Mechanistically, we show that TRAF4 targets the E3 ubiquitin ligase SMURF1, a negative regulator of BMP/SMAD signaling, for proteasomal degradation in bladder cancer cells. This was corroborated in patient samples where TRAF4 positively correlates with phospho-SMAD1/5, and negatively correlates with phospho-NFκb-p65. Lastly, we show that genetic and pharmacologic inhibition of SMURF1 inhibits the migration of aggressive mesenchymal bladder cancer cells. Implications: Our findings identify E3 ubiquitin ligase TRAF4 as a potential therapeutic target or biomarker for bladder cancer progression.

28 September 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KIKatrine Ingelshed
Katrine Ingelshed
DSDiana Spiegelberg
Diana Spiegelberg
PKPavitra Kannan
Pavitra Kannan
LPLinnéa Påvénius
Linnéa Påvénius
JHJessica Hacheney
Jessica Hacheney
SSSaikiran Sedimbi
Saikiran Sedimbi
The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14ARF. Under steady-state conditions, the two E3 ligases MDM2/MDM4 interact with and inhibit the transcriptional activity of p53. Inhibition of p53–MDM2/4 interaction to reactivate p53 in tumors with wild-type (WT) p53 has therefore been considered a therapeutic strategy. Moreover, studies indicate that p53 reactivation may synergize with radiation and increase tumor immunogenicity. In vivo studies of most MDM2 inhibitors have utilized immunodeficient xenograft mouse models, preventing detailed studies of action of these molecules on the immune response. The mouse melanoma cell line B16-F10 carries functional, WT p53 but does not express the MDM2 regulator p19ARF. In this study, we tested a p53-MDM2 protein–protein interaction inhibitor, the small molecule Navtemadlin, which is currently being tested in phase II clinical trials. Using mass spectrometry–based proteomics and imaging flow cytometry, we identified specific protein expression patterns following Navtemadlin treatment of B16-F10 melanoma cells compared with their p53 CRISPR-inactivated control cells. In vitro, Navtemadlin induced a significant, p53-dependent, growth arrest but little apoptosis in B16-F10 cells. When combined with radiotherapy, Navtemadlin showed synergistic effects and increased apoptosis. In vivo, Navtemadlin treatment significantly reduced the growth of B16-F10 melanoma cells implanted in C57Bl/6 mice. Our data highlight the utility of a syngeneic B16-F10 p53+/+ mouse melanoma model for assessing existing and novel p53-MDM2/MDM4 inhibitors and in identifying new combination therapies that can efficiently eliminate tumors in vivo.Significance: The MDM2 inhibitor Navtemadlin arrests mouse tumor growth and potentiates radiotherapy. Our results support a threshold model for apoptosis induction that requires a high, prolonged p53 signaling for cancer cells to become apoptotic.

14 March 2022 in Structure
Verified
Journal Article
Open access
PDF file
MKMargit Kaldmäe
Margit Kaldmäe
TVThibault Vosselman
Thibault Vosselman
XZXueying Zhong
Xueying Zhong
DLDilraj Lama
Dilraj Lama
GCGefei Chen
Gefei Chen
MLMichael Landreh
Michael Landreh
• p53 is poorly expressed and conformationally unstable • A spider silk domain boosts p53 translation in vitro • The spider silk-p53 fusion protein adopts a compact state and is biologically active • Reducing N-terminal disorder in fusion proteins increases expression and stability